Takeda Pharmaceutical (TAK) Non-Current Debt: 2018-2025
Historic Non-Current Debt for Takeda Pharmaceutical (TAK) over the last 8 years, with Mar 2025 value amounting to $26.0 billion.
- Takeda Pharmaceutical's Non-Current Debt fell 13.93% to $26.0 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $26.0 billion, marking a year-over-year decrease of 13.93%. This contributed to the annual value of $26.0 billion for FY2025, which is 16.12% down from last year.
- As of FY2025, Takeda Pharmaceutical's Non-Current Debt stood at $26.0 billion, which was down 16.12% from $31.0 billion recorded in FY2024.
- Over the past 5 years, Takeda Pharmaceutical's Non-Current Debt peaked at $43.5 billion during FY2021, and registered a low of $26.0 billion during FY2025.
- Its 3-year average for Non-Current Debt is $29.0 billion, with a median of $29.9 billion in 2023.
- As far as peak fluctuations go, Takeda Pharmaceutical's Non-Current Debt rose by 4.96% in 2021, and later declined by 18.87% in 2023.
- Yearly analysis of 5 years shows Takeda Pharmaceutical's Non-Current Debt stood at $43.5 billion in 2021, then decreased by 15.23% to $36.9 billion in 2022, then fell by 18.87% to $29.9 billion in 2023, then rose by 3.73% to $31.0 billion in 2024, then fell by 16.12% to $26.0 billion in 2025.